company background image
IMU

Imugene ASX:IMU Stock Report

Last Price

AU$0.046

Market Cap

AU$329.3m

7D

-8.0%

1Y

-74.4%

Updated

29 Sep, 2023

Data

Company Financials +

IMU Stock Overview

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.

IMU fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Imugene Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Imugene
Historical stock prices
Current Share PriceAU$0.046
52 Week HighAU$0.21
52 Week LowAU$0.046
Beta2.41
1 Month Change-30.30%
3 Month Change-49.45%
1 Year Change-74.44%
3 Year Change-9.80%
5 Year Change109.09%
Change since IPO-52.82%

Recent News & Updates

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Sep 19
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Recent updates

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Sep 19
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

May 30
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Jan 30
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11
Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17
A Look At Imugene's (ASX:IMU) CEO Remuneration

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24
Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Shareholder Returns

IMUAU BiotechsAU Market
7D-8.0%-0.5%-0.3%
1Y-74.4%-11.3%7.5%

Return vs Industry: IMU underperformed the Australian Biotechs industry which returned -11.4% over the past year.

Return vs Market: IMU underperformed the Australian Market which returned 5.9% over the past year.

Price Volatility

Is IMU's price volatile compared to industry and market?
IMU volatility
IMU Average Weekly Movement10.6%
Biotechs Industry Average Movement10.9%
Market Average Movement8.4%
10% most volatile stocks in AU Market15.8%
10% least volatile stocks in AU Market3.1%

Stable Share Price: IMU is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: IMU's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1986n/aLeslie Chonghttps://www.imugene.com

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in phase 2 study for gastric cancer.

Imugene Limited Fundamentals Summary

How do Imugene's earnings and revenue compare to its market cap?
IMU fundamental statistics
Market CapAU$329.34m
Earnings (TTM)-AU$39.17m
Revenue (TTM)AU$10.52m

31.3x

P/S Ratio

-8.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMU income statement (TTM)
RevenueAU$10.52m
Cost of RevenueAU$0
Gross ProfitAU$10.52m
Other ExpensesAU$49.69m
Earnings-AU$39.17m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0055
Gross Margin100.00%
Net Profit Margin-372.30%
Debt/Equity Ratio0%

How did IMU perform over the long term?

See historical performance and comparison